Haemonetics FY26 net income drops 42% to $97.31 million; revenue slips 2% to $1.33 billion

Haemonetics

Haemonetics

HAE

0.00
  • Haemonetics posted fiscal 2026 net income of USD 97.31 million, down 42% from fiscal 2025, with diluted EPS of USD 2.05 falling 38.1%.
  • Net revenues slipped 2% to USD 1.33 billion, while operating income dropped 29.3% to USD 156.73 million.
  • Gross profit rose 5.2% to USD 787.59 million, lifting gross margin to 59% from 55% a year earlier.
  • Operating expenses climbed 19.7% to USD 630.85 million, driven in part by USD 86.55 million of intangible asset impairments tied to Attune Medical.
  • Business updates included the USD 164.4 million acquisition of Vivasure, a USD 175 million share repurchase in fiscal 2026, and repayment at maturity of USD 300 million of 2026 Notes funded with cash and revolving credit borrowings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000313143-26-000050), on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.